A Phase 4 interventional study of Glycopyrronium /Indacaterol maleate in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-07-02.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 27th largest by enrollment, is one of 9 that started in 2014, is one of 11 in phase 4, and was the 41st registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 401 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 45th largest by enrollment of the 116 interventional ones that give a count, is one of 9 that started in 2014, is one of 24 in phase 4, and was the 99th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single cohort, prospective post approval study conducted on patients with COPD in Canada. The study will enroll patients that have not responded to their current treatment of tiotropium alone, or who are on the fixed dose combinations fluticasone propionate/salmeterol. Only patients for whom the physician has decided to change treatment due to lack of efficacy will be eligible to be enrolled in the study.
Also will evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient is expected to be available for 16 weeks after study enrolment
Exclusion Criteria:
Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with chronic obstructive pulmonary disorder (COPD) who are symptomatic (CAT score over 10) and who are treated with Tiotropium (SPIRIVA HANDALER) or Fluticasone propionate/Salmeterol- ADVAIR DISKUS (FDC).
Drug: Glycopyrronium /Indacaterol maleate
Drug pages: Glycopyrrolate · Indacaterol maleate
Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device
Change From Baseline in Trough (Forced Expiratory Volume (FEV1) (Pre-dose FEV1)
Primary end points: To evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients with COPD who have symptoms defined as CAT score \>10 with tiotropium monotherapy; effectiveness will be assessed as the mean change in trough FEV1 from baseline to 16 weeks. and to evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients with COPD who have symptoms defined as CAT score \>10 while on treatment with FDC of fluticasone propionate/salmeterol; effectiveness will be assessed as the mean change in trough FEV1 from baseline to 16 weeks.
Time frame: 16 weeks study
Change From Baseline in Trough FEV1 (Forced Expiratory Volume) to Week 4
Portable spirometers will be provided to investigators and they will use this device for all of their patient measurements of FEV1 during the trial
Time frame: Baseline, week 4
Single Point and Change in Baseline Dyspnea Index and Transitional Dyspnea Index (BDI/TDI)
A trained assessor interviewed the patient and graded the degree of impairment due to dyspnea (difficulty breathing). BDI/TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. The BDI was assessed at Baseline, whereas the TDI was assessed at Week 4 and Week 16.
Time frame: Baseline, Week 4, week 16
Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Assessment Questionnaire (CAT)
The CAT is an 8 item questionnaire that assesses the impact of COPD on the patient's functional status. Scores for each of the 8 items are summed to give an overall score (out of 40). The score ranges from 0-40 where higher scores represent worse health status. CAT scores ≥ 10 are associated with significantly impaired health status.
Time frame: Baseline, week 4, week 16
| Milestone | QVA149 110/50 |
|---|---|
| Started | 401 |
| Intent to treat set (itt) | 338 |
| Completed | 301 |
| Not completed | 100 |
| Withdrew: Screen failed | 24 |
| Withdrew: Adverse event | 32 |
| Withdrew: Protocol deviation | 18 |
| Withdrew: Patient withdrew consent | 12 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Administrative problems | 6 |
| Withdrew: Abnormal test procedure result | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 1 |
Primary end points: To evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients with COPD who have symptoms defined as CAT score \>10 with tiotropium monotherapy; effectiveness will be assessed as the mean change in trough FEV1 from baseline to 16 weeks. and to evaluate the real-life effectiveness of QVA149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients with COPD who have symptoms defined as CAT score \>10 while on treatment with FDC of fluticasone propionate/salmeterol; effectiveness will be assessed as the mean change in trough FEV1 from baseline to 16 weeks.
| Liter | QVA149 110/50 After Flu/Sal | QVA149 110/50 After Tio |
|---|---|---|
| Change From Baseline in Trough (Forced Expiratory Volume (FEV1) (Pre-dose FEV1) | 0.17 ± 0.397 | 0.18 ± 0.321 |
Portable spirometers will be provided to investigators and they will use this device for all of their patient measurements of FEV1 during the trial
| Liter | QVA149 110/50 After Flu/Sal | QVA149 110/50 After Tio |
|---|---|---|
| Change From Baseline in Trough FEV1 (Forced Expiratory Volume) to Week 4 | 0.12 ± 0.308 | 0.14 ± 0.267 |
A trained assessor interviewed the patient and graded the degree of impairment due to dyspnea (difficulty breathing). BDI/TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. The BDI was assessed at Baseline, whereas the TDI was assessed at Week 4 and Week 16.
| Score | QVA149 110/50 After Flu/Sal | QVA149 110/50 After Tio |
|---|---|---|
| BDI week 0 | 6.5 ± 2.07 | 6.8 ± 2.09 |
| TDI week 4 | 2.2 ± 2.72 | 2.0 ± 2.38 |
| TDI week 16 | 2.9 ± 3.28 | 2.4 ± 2.78 |
The CAT is an 8 item questionnaire that assesses the impact of COPD on the patient's functional status. Scores for each of the 8 items are summed to give an overall score (out of 40). The score ranges from 0-40 where higher scores represent worse health status. CAT scores ≥ 10 are associated with significantly impaired health status.
| Score | QVA149 110/50 After Flu/Sal | QVA149 110/50 After Tio |
|---|---|---|
| Week 4 | -5.9 ± 7.55 | -4.7 ± 5.71 |
| Week 16 | -8.2 ± 8.34 | -5.9 ± 6.44 |
Collected over From week 0 to week 16. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| QVA149 110/50 | 0/373 (0%) | 12/373 (3.2%) | 56/373 (15%) |
| Event | QVA149 110/50 |
|---|---|
| PneumoniaInfections and infestations | 4/373 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/373 |
| AnaemiaBlood and lymphatic system disorders | 1/373 |
| Lymphadenopathy mediastinalBlood and lymphatic system disorders | 1/373 |
| Cardiac failureCardiac disorders | 1/373 |
| Cardiac failure congestiveCardiac disorders | 1/373 |
| Sinus tachycardiaCardiac disorders | 1/373 |
| Intestinal ischaemiaGastrointestinal disorders | 1/373 |
| GastroenteritisInfections and infestations | 1/373 |
| InfluenzaInfections and infestations | 1/373 |
| Event | QVA149 110/50 |
|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 13/373 |
| Upper respiratory tract infectionInfections and infestations | 11/373 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/373 |
| BronchitisInfections and infestations | 9/373 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/373 |
| DyspepsiaGastrointestinal disorders | 4/373 |
| NauseaGastrointestinal disorders | 4/373 |
| DizzinessNervous system disorders | 4/373 |
| HypertensionVascular disorders | 4/373 |
The ITT included all patients who received the study treatment and returned for ≥ 1 post baseline visit
| Age, Continuous(Years) | ULTIBRO BREEZHALER |
|---|---|
| Mean | 66.1 ± 9.46 |
| Sex: Female, Male(Participants) | ULTIBRO BREEZHALER |
|---|---|
| Female | 149 |
| Male | 189 |
| Race (NIH/OMB)(Participants) | ULTIBRO BREEZHALER |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 330 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2014 to primary completion in Apr 2017, 31 months.
Results were first posted in Jun 2019, 2 years 2 months after primary completion.
Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 31 months is above that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glycopyrrolate · Indacaterol maleate
Pulmonary Disease, Chronic Obstructive →